Hurel Corp Information

HµREL® develops and sells advanced micro-liver tissue constructs of primary cryopreserved hepatocytes co-cultured with nonparenchymal stromal cells, in a variety of species and formats. With a focus on lab practicality and convenience, HµREL delivers its products ready for use with no preparatory tissue culture and includes all necessary media with each shipment. HµREL’s stable, robust, high-functioning metabolically competent models have been demonstrated to endure for much longer time periods than traditional hepatic systems. These robust micro-tissues allow a variety of novel in vitro experiments, including: studies of clearance rates of low-clearing compounds; metabolite generation studies with the ability to produce more in vivo relevant metabolites; long-term inhibition assays for cyp contribution; long-term DDI studies; and the ability of repeat-dosing studies to probe mechanism-based metabolic enzyme activity, or sub-acute/chronic toxicities, including cholestatic liabilities among others. HµREL’s robust primary hepatic co-cultures are shipped directly to our customers throughout the world from our corporate office in North Brunswick, NJ. HµREL also provides in vitro drug metabolism and toxicity services featuring HµREL's primary hepatic co-culture platforms. These services include: HµRELflux™ - hepatobiliary research services based on HµREL’s new and patented biliary efflux transporter assay method HµRELTox™ - 14-day multiparametric in vitro toxicity screening service, featuring ACEA Biosciences xCELLigence Real-Time Cell Analysis, with additional hepatocytes specific Albumin functional assays at multiple time-points, and terminal ATP endpoint after 14 days. HµREL maintains corporate headquarters and labs in North Brunswick, NJ, with additional offices in Pittsburgh, PA and Beverly Hills, CA.